Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil for cardiac remodeling in Cushing's syndrome cardiomyopathy
2015-004497-15Phase 2Active
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tadalafil in Cushing's syndrome, sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Primary endpoint: Change in left ventricular torsion angle. Started Jan 2018; status: active.
02
Drugs
tadalafil
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on 2015-004497-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004497-15.